Corrigendum: Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation
- PMID: 29508697
- DOI: 10.3310/hta21020-c201802
Corrigendum: Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation
Erratum for
-
Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation.Health Technol Assess. 2017 Jan;21(2):1-218. doi: 10.3310/hta21020. Health Technol Assess. 2017. PMID: 28105986 Free PMC article.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources